Close Menu

NEW YORK – Immune Therapeutics announced on Monday that it plans to acquire development-stage oncology company Aletheia Therapeutics, and the combined entity will focus on advancing precision oncology treatments. 

Immune will acquire all outstanding shares of Aletheia in exchange for Immune common stock. Aletheia's management team and select board members will join the leadership of the combined company. The deal is expected to close in the first quarter of 2020. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.